Komodo Health
IntegratedAI NativePrivateUpdated November 15, 2026330 million patient journeys turned into the pharmaceutical industry's most powerful AI analytics engine.
- Website
- komodohealth.com
- Founded
- 2014
- CEO
- Arif Nathoo and Web Sun (co-CEOs)
- HQ
- San Francisco, CA, United States
- Stage
- Series F
- Revenue
- Not disclosed
- Total Funding
- $587M
- Employees
- 201-500
Executive Summary
Updated Nov 1, 2026
What they do
- Maintains the Healthcare Map, de-identified journeys for over 330 million patients
- Sells the MapLab platform with no-code and natural-language tools for life sciences analytics
- Offers Marmot, an AI engine for healthcare that turns questions into checkable analyses
Why it matters
- Links claims, EHR, lab and provider data into one longitudinal patient view
- Lets commercial, medical and real-world-evidence teams get insights without big analyst backlogs
- Partners include Alnylam (now enterprise-wide), GeneDx, NCQA and Nasdaq
Best fit
- Pharma and biotech commercial, market access and brand analytics teams
- Real-world-evidence and HEOR groups needing large linked US patient datasets
- Rare disease and specialty drug makers sizing patient populations and HCP targets
Watch-outs
- Coverage is mainly US data, so global programs will need other sources
- Headcount fell about 5% and no new funding round reported since 2022
- Marmot AI launched only in 2025, so verify output accuracy and auditability
Products & Offerings
Healthcare Map
Komodo's core asset: de-identified, longitudinal US data on more than 330 million patient journeys, linking claims, EHR, lab and provider data.
Marmot
Komodo's AI engine built for healthcare, which turns plain-language questions into analyses on the Healthcare Map that users can check, with versions for commercial and other life sciences teams.
MapLab
Komodo's enterprise analytics platform, a suite of apps and tools for querying the Healthcare Map, building patient cohorts and analyzing data.
MapAI
An AI assistant built into MapLab that uses natural language processing so non-technical users can ask questions of the healthcare data in plain language.
MapExplorer
A no-code MapLab tool for exploring patient populations, treatment patterns and provider data without writing queries.
Latest News
TipRanks · 1 month ago
PositiveTipRanks · 2 months ago
PositiveTipRanks · 2 months ago
PositiveTipRanks · 2 months ago
PositiveTipRanks · 2 months ago
PositiveUpdated Nov 1, 2026
Komodo Health is one of the main US sources of real-world patient data for life sciences, and its MapLab and Marmot AI layers make that data usable beyond specialist analysts. Pharma and biotech buyers of commercial or real-world-evidence analytics should include it alongside IQVIA and similar data providers. During evaluation, check how complete the data is for your therapy areas, how well the AI shows its work, and the full cost of licensing.
Signal Provenance
Latest observation date and source for each signal category
| Signal Category | Last Updated | Source |
|---|---|---|
Funding Signals Last funding round, Funding stage | Nov 14, 2026 | Cited web research |
Hiring Velocity Headcount, Headcount growth | Nov 13, 2026 | Research agents (estimate) |
Technical Output Research papers, GitHub activity | Nov 15, 2026 | Hugging Face Hub + news feed + research agents |
News Sentiment News mentions, News sentiment | Nov 15, 2026 | Verified news feed |
Partnership Signals Enterprise partnerships, Distribution partners | Jun 5, 2026 | Research agents (estimate) |
Revenue Indicators ARR estimate, Revenue growth | Nov 15, 2026 | Research agents (estimate) |
Leadership Signals CEO tenure, Founder-led | Nov 15, 2026 | Research agents (estimate) |
Competitive Position Category rank, Market share | Nov 15, 2026 | Research agents (estimate) |
Why this Bluescore?
6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology
Komodo Health's Bluescore of 38.4 rests most on Investment Momentum (6.1, 72nd percentile) and Business Model & Revenue (4.5, 61st percentile). Its weakest area is Talent & Research (2.0, 1st percentile).
In plain English
Komodo Health has a Bluescore of 38.4 and ranks #199 of 247 overall, down 4 places since yesterday. Its strongest contributions come from Investment Momentum, which scores 6.1 of 10 at the 72nd percentile, and Business Model & Revenue, which scores 4.5 of 10 at the 61st percentile, while Talent & Research (2.0 of 10, 1st percentile) and Customer Adoption (3.8 of 10, 4th percentile) hold it back most. The biggest lever is Product Depth, which carries a 21% weight and has 13.1 points still available, so moving its 3.8 of 10 score would add more to the Bluescore than any other dimension.
Written by AI from the scores below and checked against them; updated nightly.
Traction Signals
Last Round
Series F
Risks
Updated Nov 1, 2026